The Share

The Diamyd Medical share is traded on NASDAQ Stockholm First North (ticker : DMYD B).

About First North

First North is an alternative marketplace operated by an exchange within the NASDAQ OMX group. Companies on First North are not subject to the same rules as companies on the regulated main market. Instead they are subject to a less extensive set of rules and regulations adjusted to small growth companies. The risk in investing in a company on First North may therefore be higher than investing in a company on the main market. All companies with shares traded on First North have a Certified Adviser who monitors that the rules are followed. The Exchange approves the application for admission to trading.

Certified Adviser at First North

FNCA Sweden AB, Humlegårdsgatan 5, Box 5807, SE-102 48 Stockholm. Tel: 08-528 00 399.

Annual Report

  November 3, 2016
  Quarterly Report III, June 28, 2017

Dear Shareholders and readers

The oversubscribed rights issue means Diamyd Medical has a solid base ahead of this autumn’s focus on DIAGNODE-2, a placebo-controlled trial in which the diabetes vaccine is administered into the lymph nodes of children and young adults that have recently been diagnosed with type 1 diabetes. The Swedish Medical Products Agency has approved the study, and together with TFS, our chosen Contract Research Organization, we are continuing preparations for the forthcoming enrollment of patients.

The oversubscribed rights issue means Diamyd Medical has a solid base ahead of DIAGNODE-2.
Ulf Hannelius, President and CEO

Event Calendar

 Dates for financial information and other events
November 13, 2017
Stora Aktiedagen
Event by Aktiespararna, Hotel Birger Jarl, Stockholm
November 30, 2017
Annual General Meeting

Financial Calendar

 October 11, 2017
Financial Statement 2016/2017
 November 9, 2017
Annual Report 2016/2017
 January 24, 2018
Quarterly Report 1 2016/2017
 March 28, 2018
Quarterly Report 2 2017/2018
 June 27, 2018
Quarterly Report 3 2017/2018
 October 10, 2018
Financial statement 2017/2018
 

We are dedicated to finding a cure for autoimmune diabetes through pharmaceutical development and investments in medical and stem cell technologies

 

Ten largest shareholders as of July 31, 2017

ShareholderA SharesB SharesCapital %Votes %
Essen-Möller, Anders 2 130 186 6 110 867 14.63 36.31
Avanza Pension 7 076 877 12.56 9.37
Lindkvist, Bertil 6 056 858 10.75 8.02
Nordnet Pensionsförsäkring AB 2 419 911 4.30 3.20
Swedbank Försäkring 672 980 1.19 0.89
Relbo AB 396 292 0.70 0.52
Försäkrings AB Skandia 350 874 0.62 0.46
Arandi Development AB 350 000 0.62 0.46
Wellwing, Stig 350 000 0.62 0.46
Bohlin, Lennart 345 571 0.61 0.46
Remaining shareholders 30 073 488 53.4 39.8
Total 2 130 186 54 203 718 100.0 100.0